The opioid drug epidemic and sickle cell disease: Guilt by association

Pain Medicine (United States)

Volumn 17, Issue 10, 2016, Pages 1793-1798

  Ruta, Nadia S ^a   Ballas, Samir K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; HYDROMORPHONE; LONG ACTING DRUG; MORPHINE; OPIATE; OXYCODONE; PETHIDINE; SHORT ACTING DRUG; NARCOTIC ANALGESIC AGENT;

AFRICAN AMERICAN; ANALGESIA; ARTICLE; ATTITUDE TO HEALTH; CANCER PAIN; CAUCASIAN; CAUSE OF DEATH; CHRONIC PAIN SYNDROME; DEATH; DRUG OVERDOSE; EMERGENCY CARE; EPIDEMIC; ETHNIC DIFFERENCE; FIBROMYALGIA; HOME CARE; HOSPITALIZATION; HUMAN; LOW BACK PAIN; MIGRAINE; OPIATE ADDICTION; PAIN; PAIN ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; QUALITY OF LIFE; SICKLE CELL ANEMIA; PATIENT PARTICIPATION; PROCEDURES;

ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PAIN MANAGEMENT; PATIENT PARTICIPATION;

EID: 85015140066     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1093/pm/pnw074     Document Type: Article

References (71)

1. Centers for Disease Control and Prevention. Vital signs: Overdoses of prescription opioid pain relievers-United States, 1999-2008. Morb Mortal Wkly Rep 2011; 60: 1487-92.
2. Chen LH, Hedegaard H. QuickStats: Rates of Deaths from Drug Poisoning and Drug Poisoning Involving Opioid Analgesics-United States, 1999-2013. Morb Mortal Wkly Rep 2015; 64: 32.
3. McCarthy M. Opioid overdose deaths rose fivefold among US women in 10 years. BMJ 2013; 347: f4415.
4. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372: 241-8.
5. McCann DJ, Skolnick P. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372: 1572-3.
6. Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief 2014; 1-8.
7. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309: 657-9.
8. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annu Rev Public Health 2015; 36: 559-74.
9. Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012; 15: ES9-38.
10. Centers for Disease Control and Prevention. CDC Multiple cause of death data, 1999-2013. 2015.
11. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-21.
12. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: A cohort study. Ann Intern Med 2010; 152: 85-92.
13. Yokell MA, Delgado MK, Zaller ND, et al. Presentation of prescription and nonprescription opioid overdoses to US emergency departments. JAMA Intern Med 2014; 174: 2034-7.
14. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med 2012; 13: 562-70.
15. Rich BA, Webster LR. A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose. Pain Med 2011; 12(suppl 2): S59-65.
16. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-34.
17. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-30.
18. Pentin PL. Drug seeking or pain crisis? Responsible prescribing of opioids in the emergency department. Virtual Mentor 2013; 15: 410-5.
19. Labbe E, Herbert D, Haynes J. Physicians’ attitude and practices in sickle cell disease pain management. J Palliat Care 2005; 21: 246-51.
20. Pack-Mabien A, Labbe E, Herbert D, Haynes J Jr. Nurses’ attitudes and practices in sickle cell pain management. Appl Nurs Res 2001; 14: 187-92.
21. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: Perceptions of medical practitioners. J Pain Symptom Manage 1997; 14: 168-74.
22. Waldrop RD, Mandry C. Health professional perceptions of opioid dependence among patients with pain. Am J Emerg Med 1995; 13: 529-31.
23. Zempsky WT. Treatment of sickle cell pain: Fostering trust and justice. JAMA 2009; 302: 2479-80.
24. Alao AO, Westmoreland N, Jindal S. Drug addiction in sickle cell disease: Case report. Int J Psychiatry Med 2003; 33: 97-101.
25. Bauchner H. Race, poverty, and medicine in the United States. JAMA 2015; 313: 1423.
26. Biedrzycki OJ, Bevan D, Lucas S. Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/beta-thalassemia and acute chest syndrome: A case report and review of the literature. Am J Forensic Med Pathol 2009; 30: 188-90.
27. Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses - a U.S. epidemic. Morb Mortal Wkly Rep 2012; 61: 10-3.
28. Centers for Disease Control and Prevention. Vital signs: Overdoses of prescription opioid pain relievers and other drugs among women-United States, 1999-2010. Morb Mortal Wkly Rep 2013; 62: 537-42.
29. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: Evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage 2004; 27: 156-69.
30. Feliu MH, Wellington C, Crawford RD, et al. Opioid management and dependency among adult patients with sickle cell disease. Hemoglobin 2011; 35: 485-94.
31. Gorman K. Sickle cell disease. Do you doubt your patient’s pain? Am J Nurs 1999; 99: 38-43; quiz 44.
32. Green CR, Anderson KO, Baker TA, et al. The unequal burden of pain: Confronting racial and ethnic disparities in pain. Pain Med 2003; 4: 277-94.
33. Gregg J. A startling injustice: Pain, opioids, and addiction. Ann Intern Med 2015; 162: 651-2.
34. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300: 2613-20.
35. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer 2013; 60: 1482-6.
36. Johnson EM, Lanier WA, Merrill RM, et al. Unintentional prescription opioid-related overdose deaths: Description of decedents by next of kin or best contact, Utah, 2008-2009. J Gen Intern Med 2013; 28: 522-9.
37. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med 2012; 6: e41-7.
38. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep 2013; 128: 110-6.
39. Layne RD, Pellegrino RJ, Lerfald NM. Prescription opioids and overdose deaths. JAMA 2009; 301: 1766-7. author reply 67-9.
40. Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: Role for both daily and total opioid dose? J Pain 2015; 16: 318-25.
41. Napolez A. Narcotic dependency in the sickle cell population. Am J Emerg Med 2001; 19: 329.
42. Nelson SC, Hackman HW. Race matters: Perceptions of race and racism in a sickle cell center. Pediatr Blood Cancer 2013; 60: 451-4.
43. Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012; 13: 87-95.
44. Telfer P, Bahal N, Lo A, Challands J. Management of the acute painful crisis in sickle cell disease- a reevaluation of the use of opioids in adult patients. Br J Haematol 2014; 166: 157-64.
45. Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011; 1-8.
46. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med 2011; 12(suppl 2): S26-35.
47. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033-48.
48. Expert Panel Report. Evidence-based management of sickle cell disease. In: U.S. Department of Health and Human Services. Bethesda, MD: National Heart, Lung, and Blood Institute; 2014.
49. National Heart Lung and Blood Institute (US). Sickle Cell Research for Treatment and Cure. NIH Publication No 02-5214. 2002: 15.
50. Ballas SK. Chapter 18: Civil Litigation and Sickle Cell Pain. In: Sickle Cell Pain, 2nd edition. Washington, DC: International Association for the Study of Pain; 2014: 571-99.
51. Tanabe P, Myers R, Zosel A, et al. Emergency department management of acute pain episodes in sickle cell disease. Acad Emerg Med 2007; 14: 419-25.
52. Chestnut DE. Perceptions of ethnic and cultural factors in the delivery of services in the treatment of sickle cell disease. J Health Soc Policy 1994; 5: 215-42.
53. Dorsey C, Phillips KD, Williams C. Adult sickle cell patients’ perceptions of nurses’ caring behaviors. ABNF J 2001; 12: 95-100.
54. McCracken LM, Matthews AK, Tang TS, Cuba SL. A comparison of blacks and whites seeking treatment for chronic pain. Clin J Pain 2001; 17: 249-55.
55. Green CR, Hart-Johnson T. The impact of chronic pain on the health of black and white men. J Natl Med Assoc 2010; 102: 321-31.
56. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005; 79: 17-25.
57. American Society of Hematology. Proposed 2016 Guidelines for Prescribing Opioids for Chronic Pain (Docket No. CDC-2015-0112). 2016.
58. Manci EA, Culberson DE, Yang YM, et al. Causes of death in sickle cell disease: An autopsy study. Br J Haematol 2003; 123: 359-65.
59. Darbari DS, Wang Z, Kwak M, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One 2013; 8: e79923.
60. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol 2014; 89: 530-5.
61. Ballas SK, Bauserman RL, McCarthy WF, et al. Hydroxyurea and acute painful crises in sickle cell anemia: Effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage 2010; 40: 870-82.
62. Branch WT Jr. A piece of my mind. The ethics of patient care. JAMA 2015; 313: 1421-2.
63. Wong WF, LaVeist TA, Sharfstein JM. Achieving health equity by design. JAMA 2015; 313: 1417-8.
64. Hughes HK, Korthuis PT, Saha S, et al. A mixed methods study of patient-provider communication about opioid analgesics. Patient Educ Couns 2015; 98: 453-61.
65. Ballas SK. Sickle Cell Pain, 2nd edition. Washington, DC: International Association for the Study of Pain; 2014.
66. Ballas SK. Treatment of pain in adults with sickle cell disease. Am J Hematol 1990; 34: 49-54.
67. Krishnamurti L, Smith-Packard B, Gupta A, et al. Impact of individualized pain plan on the emergency management of children with sickle cell disease. Pediatr Blood Cancer 2014; 61: 1747-53.
68. McCaffery M, Ferrell BR. Influence of professional vs. personal role on pain assessment and use of opioids. J Contin Educ Nurs 1997; 28: 69-77.
69. Bediako SM, Moffitt KR. Race and social attitudes about sickle cell disease. Ethn Health 2011; 16: 423-9.
70. Hill CS Jr. The barriers to adequate pain management with opioid analgesics. Semin Oncol 1993; 20: 1-5.
71. Whalen J. Holy Grail: Pain pills without the high. Wall Street Journal. New York, NY; March 17, 2015.